Vasohibin-2与肝癌肝移植术后复发转移及预后的关系
|
摘要
目的探讨Vasohibin-2在HCC组织中的表达及其与肝癌肝移植术后复发转移和预后的关系。方法采用免疫组化和Western blot方法检测34例HCC组织及其PCLT中Vasohibin-2的表达。分析Vasohibin-2与HCC的结节数目、静脉浸润、肿瘤细胞分化程度和肝外转移等临床病理特征的关系;通过随访分析Vasohibin-2的表达与肝癌肝移植患者术后复发转移及预后的关系。结果 Vasohibin-2定位于细胞质,免疫组化及Western blot均显示HCC组Vasohibin-2的阳性表达率高于PCLT组,差异具有统计学意义(P<0.05)。34例HCC中Vasohibin-2蛋白表达量(196.6±31.4)高于PCLT组织中Vasohibin-2蛋白表达量(108.9±24.3),差异具有统计学意义(P<0.05);Vasohibin-2高表达组(n_1=16)和Vasohibin-2低表达组(n_2=18)在结节数目(P<0.05)、静脉浸润(P<0.05)、肿瘤细胞分化程度(P<0.05)和肝外转移(P<0.05)方面的差异具有统计学意义。随访资料分析结果显示Vasohibin-2高表达组的复发转移率高于低表达组(P<0.05),高表达组的生存率低于低表达组(P<0.05),差异具有统计学意义。结论 Vasohibin-2在HCC中表达上调;Vasohibin-2的表达与肝癌肝移植术后复发转移密切相关,有可能成为预测肝癌肝移植术后复发转移及预后的潜在指标,为防治肝癌肝移植术后复发转移开辟新的途径。
Objective To analyze the expression of vasohibin-2 in HCC tissues and the correlation between its expression and clinical pathological characteristic as well as prognosis of HCC liver transplant. Methods Vasohibin-2 expression was determined in 34 HCC tissues and their PCLT by IHC( immunohistochemistry) and Western blotting. Follow-up study analyze the expression of vasohibin-2 in HCC tissue and the correlation between its expression and clinical pathological characteristic( numbers of tumor nodes、vien invasion、tumor cell differentiation and metastasis) as well as prognosis of HCC liver transplant. Results Vasohibin-2 located in the plasma of tumor cells. Vasohibin-2 positive expression ratio in HCC was higher than PLCT detected by IHC and Western blot,there were significant difference( P < 0. 05). The expression levels of vasohibin-2 protern on HCC tissues were higher than PCLT( 196. 6 ± 31. 4 VS 108. 9 ± 24. 3),there were significant difference( P < 0. 05). The higher expression of vasohibin-2 correlated with numbers of tumor nodes、vien invasion、tumor cell differentiation and metastasis( P < 0. 05). Follow-up study indicated that the recurrence ratio of high expression group was higher than low expression group( P < 0. 05),the survival time of high expression group was shorter than low expression group( P < 0. 05). Conclusion Vasohibin-2 expression up regulated in HCC. High expression of vasohibin-2 attributed to recurrence/metastasis of HCC liver transplant. The determination of vasohibin-2 can be of great value in predicting the prognosis and recurrence/metastasis of patients with HCC liver transplant.
Objective To analyze the expression of vasohibin-2 in HCC tissues and the correlation between its expression and clinical pathological characteristic as well as prognosis of HCC liver transplant. Methods Vasohibin-2 expression was determined in 34 HCC tissues and their PCLT by IHC( immunohistochemistry) and Western blotting. Follow-up study analyze the expression of vasohibin-2 in HCC tissue and the correlation between its expression and clinical pathological characteristic( numbers of tumor nodes、vien invasion、tumor cell differentiation and metastasis) as well as prognosis of HCC liver transplant. Results Vasohibin-2 located in the plasma of tumor cells. Vasohibin-2 positive expression ratio in HCC was higher than PLCT detected by IHC and Western blot,there were significant difference( P < 0. 05). The expression levels of vasohibin-2 protern on HCC tissues were higher than PCLT( 196. 6 ± 31. 4 VS 108. 9 ± 24. 3),there were significant difference( P < 0. 05). The higher expression of vasohibin-2 correlated with numbers of tumor nodes、vien invasion、tumor cell differentiation and metastasis( P < 0. 05). Follow-up study indicated that the recurrence ratio of high expression group was higher than low expression group( P < 0. 05),the survival time of high expression group was shorter than low expression group( P < 0. 05). Conclusion Vasohibin-2 expression up regulated in HCC. High expression of vasohibin-2 attributed to recurrence/metastasis of HCC liver transplant. The determination of vasohibin-2 can be of great value in predicting the prognosis and recurrence/metastasis of patients with HCC liver transplant.
引文
[1]Giannelli G,Antonaci S.Novel concepts in hepatocellular carcinoma:from molecular research to clinical practice[J].J Clin Gastroenterol,2006,40(9):842-846.
[2]Yang LY,Lu WQ,Huang GW,et al.Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma[J].BMC Cancer,2006,6:110.
[3]Liotta LA,Kohn EC.Role of myofibroblasts at the invasion front[J].Biol Chem,2002,383(1):55-67.
[4]郑树森,吴健.肝癌肝移植的标准及讨论[A];浙江省第二十次肿瘤防治学术年会暨首届浙江肿瘤学术周论文汇编[C].2006.
[5]Shen Z,Kauttu T,Seppnen H,et al.Vasohibin-1 and vasohibin-2 expression in gastric cancer cells and TAMs[J].Med Oncol,2012,29(4):2718-2726.
[6]Sato Y.The vasohibin family a novel family for angiogen-esis regulation[J].J Biochem,2013,153(1):5-11.
[7]Takahashi Y,Koyanagi T,Suzuki Y,et al.Vasohibin-2 expressed in human serous ovarian adenocarcinoma ac-celerates tumor growth by promoting angiogenesis[J].Mol Cancer Res,2012,10(9):1135-1146.
[8]Koyanagi T,Saga Y,Takahashi Y,et al.Downregulation of vasohibin-2,a novel angiogenesis regulator,suppresses tumor growth by inhibiting angiogenesis in endometrial cancer cells[J].Oncol Lett,2013,5(3):1058-1062.
[9]Koyanagi T,Suzuki Y,Saga Y.In vivo delivery of siRNA targeting vasohibin-2 decreases tumor angiogenesis and suppresses umor growth in ovarian cancer[J].Cancer Sci,2013,104(12):1705-1710.
[10]Pirisi M,Leutner M,Pinato DJ,et al.Reliability andreproducibility of the edmondson grading of hepatocellularcarcinoma using paired core biopsy and surgical resectionspecimens[J].Arch Pathol Lab Med,2010,134(12):1818-1822.
[11]De Wever O,Mareel M.Role of myofibroblasts at the invasion front[J].Biol Chem,2002,383(1):55-67.
[12]Shimada K,Sano T,Sakamoto Y,et al.A long term followup and management study of hepatocellular carcinoma patients surviving for 10 years or longer after curative hepatectomy[J].Cancer,2005,104(9):1939-1947.
[13]杨连粤,刘合利,黄耿文,等.孤立性大肝癌分子病理特征的初步研究[J].中华实验外科杂志,2004,21(1):94-96.
[14]Semela D,Dufour JF.Angiogenesis and hepatocellular carcinoma[J].J Hepatol,2004,41(5):864-880.
[15]Folkman J.Angiogenesis:an organizing principle for drugdiscovery[J].Nat Rev Drug Discov,2007,6(4):273-286.
[16]Llovet JM,Ricci S,Mazzaferro V,et al.Sorafenib inadvanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.
[2]Yang LY,Lu WQ,Huang GW,et al.Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma[J].BMC Cancer,2006,6:110.
[3]Liotta LA,Kohn EC.Role of myofibroblasts at the invasion front[J].Biol Chem,2002,383(1):55-67.
[4]郑树森,吴健.肝癌肝移植的标准及讨论[A];浙江省第二十次肿瘤防治学术年会暨首届浙江肿瘤学术周论文汇编[C].2006.
[5]Shen Z,Kauttu T,Seppnen H,et al.Vasohibin-1 and vasohibin-2 expression in gastric cancer cells and TAMs[J].Med Oncol,2012,29(4):2718-2726.
[6]Sato Y.The vasohibin family a novel family for angiogen-esis regulation[J].J Biochem,2013,153(1):5-11.
[7]Takahashi Y,Koyanagi T,Suzuki Y,et al.Vasohibin-2 expressed in human serous ovarian adenocarcinoma ac-celerates tumor growth by promoting angiogenesis[J].Mol Cancer Res,2012,10(9):1135-1146.
[8]Koyanagi T,Saga Y,Takahashi Y,et al.Downregulation of vasohibin-2,a novel angiogenesis regulator,suppresses tumor growth by inhibiting angiogenesis in endometrial cancer cells[J].Oncol Lett,2013,5(3):1058-1062.
[9]Koyanagi T,Suzuki Y,Saga Y.In vivo delivery of siRNA targeting vasohibin-2 decreases tumor angiogenesis and suppresses umor growth in ovarian cancer[J].Cancer Sci,2013,104(12):1705-1710.
[10]Pirisi M,Leutner M,Pinato DJ,et al.Reliability andreproducibility of the edmondson grading of hepatocellularcarcinoma using paired core biopsy and surgical resectionspecimens[J].Arch Pathol Lab Med,2010,134(12):1818-1822.
[11]De Wever O,Mareel M.Role of myofibroblasts at the invasion front[J].Biol Chem,2002,383(1):55-67.
[12]Shimada K,Sano T,Sakamoto Y,et al.A long term followup and management study of hepatocellular carcinoma patients surviving for 10 years or longer after curative hepatectomy[J].Cancer,2005,104(9):1939-1947.
[13]杨连粤,刘合利,黄耿文,等.孤立性大肝癌分子病理特征的初步研究[J].中华实验外科杂志,2004,21(1):94-96.
[14]Semela D,Dufour JF.Angiogenesis and hepatocellular carcinoma[J].J Hepatol,2004,41(5):864-880.
[15]Folkman J.Angiogenesis:an organizing principle for drugdiscovery[J].Nat Rev Drug Discov,2007,6(4):273-286.
[16]Llovet JM,Ricci S,Mazzaferro V,et al.Sorafenib inadvanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.